Autoinjectors Market to Hit USD 3.02 Billion by 2030

The global autoinjectors market, valued at US$1.08B in 2023, is forecasted to grow at a 13.6%% CAGR
The global autoinjector devices market [https://www.marketsandmarkets.com/Market-Reports/autoinjector-market-173991724.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=autoinjectormarket] is projected to reach USD 3.02 billion in 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulations market is estimated to reach USD 134.27 billion in 2030 from USD 67.30 billion in 2024, growing at a CAGR of 12.2%. Technology advancements in the autoinjector devices, such as improved design, addition of connectivity features for data tracking, bluetooth connectivity, dosage reminders are some of the factors increasing adoption of autoinjectors subsequently driving market growth. The prevalence of severe allergies has led to a significant demand for product like EpiPen (epinephrine autoinjectors) are essential for emergency treatment in developed and developing countries. Additionally, rising prevalence of chronic diseases and increasing adoption of biologics is further likely to boost the demand for the autoinjectors market. Furthermore, favourable regulatory policies and reimbursement policies in North America and Europe are some of the factors increasing adoption of autoinjectors in the region subsequently giving momentum to market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=autoinjectormarket]

The Rheumatoid Arthritis accounted for the dominant share

Based on the therapy area, the autoinjectors market is divided into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, obesity, and other therapy areas. In 2023, the rheumatoid arthritis segment dominated the autoinjectors market and obesity segment is anticipated to grow at highest CAGR during the forecast period. Growing prevalence of rheumatoid arthritis and availability of autoinjectors for the treatment of this condition are some of the major factors driving the growth of the market. Obesity segment is likely to grow at faster pace owing to launch of novel products and rise in adoption of autoinjectors for weight management. As of August 2024, according to Australia's Therapeutic Goods Administration Wegovy (semaglutide), will be available in Australia from early August 2024.

Reusable autoinjectors is likely to grow at significant CAGR during the forecast period for 2024-2030.

Based on the usage, the autoinjectors market is further categorized into reusable and disposable autoinjectors. In 2023, the disposable segment accounted for the fastest-growing share of the usage segment of autoinjectors market. Ease of use, growing demand in self-administration and reduced risk of cross-contamination or infection is driving the growth of the disposable autoinjectors market. Innovations in reusable autoinjector such as ergonomic designs, digital interfaces, and enhanced safety features is rising adoption of reusable autoinjectors in developing countries.

Europe: The second-largest region in the autoinjectors market.

The European autoinjectors market held second-largest market share autoinjectors market globally. The favorable reimbursement and regulatory scenario is giving momentum to the market growth in European region. Furthermore, regulatory support for biologics and biosimilars by the EMA, rising prevalence of chronic diseases, increasing adoption of autoinjectors, Technological advancements, including smart autoinjectors with digital connectivity among patient population is likely to boost the market growth in the region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=autoinjectormarket]

Furthermore, presence of key market players such as SHL Medical, Ypsomed is likely to contribute to the growth of the market.

Autoinjectors market players for devices include SHL Medical AG (Switzerland), Ypsomed AG (Switzerland), Becton, Dickinson and Company (BD) (US), Recipharm AB (Sweden), West Pharmaceutical Services, Inc.(US), Phillips-Medisize (US), Halozyme, Inc. (US), Owen Mumford Ltd. (UK), Gerresheimer AG (Germany), Haselmeier (Germany), Oval Medical Technologies Ltd. (UK), Kaleo, Inc. (US), Solteam Incorporation Co., Ltd. (China), Elcam Drug Delivery Devices (Israel), Crossject (France), Jabil, Inc. (US), Congruence Medical Solutions LLC (US), Midas Pharma GMBH (Germany). Some of the major market players for finished formulations covered in this chapter include Abbvie Inc. (US), Eli Lilly and Company (US), Amgen Inc. (US), Novo Nordisk A/S (Denmark), Jonhson & Jonhson Services Inc. (US), Sanofi (France), GSK plc (UK).

SHL Medical AG is the leading market player in the autoinjector devices market. The company offers a wide range of autoinjector products for low to high-volume formulations. The has a strong emphasis on the launch of technologically advanced autoinjector devices in the market, contributing towards the company's dominant position in the market. Furthermore, the company is planning to ramp up its production capacity in order to meet the demand for the autoinjectors in coming years.

Ypsomed AG is one of the dominant players in the global autoinjector market. Ypsomed offers an extensive product portfolio of self-injection device systems and infusion systems. The company's strong focus on geographic presence and launch of patient-centric autoinjector products influence to dominant market share. Ypsomed generally focuses on employing inorganic and organic growth strategies to maintain its strong position in the market. The company has alliances and supply agreements with a few of the leading drug manufacturers globally. For instance, in September 2023, Ypsomed and Novo Nordisk entered into a long-term supply agreement for an massive quantity of autoinjectors.

Becton, Dickinson and Company (BD) is one of the prominent players in the autoinjector devices market. BD offers diversified drug delivery systems. The company's dominant position in the market is due to its strong brand presence, innovative product offerings, and strategies adopted by the company, such as collaborations, partnerships, and agreements. Additionally, a strong focus on expanding the company's presence in emerging markets is further likely to strengthen BD's market position in the autoinjectors market. Furthermore, BD leverages its extensive global distribution network worldwide. This includes partnerships with local distributors and direct sales channels.

For more information, inquire now! Inquire Now [https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=173991724&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=autoinjectormarket]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=autoinjectors-market-to-hit-usd-302-billion-by-2030]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/autoinjector-market-173991724.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.